BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 29447370)

  • 1. Management of gout by UK rheumatologists: a British Society for Rheumatology national audit.
    Roddy E; Packham J; Obrenovic K; Rivett A; Ledingham JM
    Rheumatology (Oxford); 2018 May; 57(5):826-830. PubMed ID: 29447370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy.
    Pascart T; Latourte A; Flipo RM; Chalès G; Coblentz-Baumann L; Cohen-Solal A; Ea HK; Grichy J; Letavernier E; Lioté F; Ottaviani S; Sigwalt P; Vandecandelaere G; Richette P; Bardin T
    Joint Bone Spine; 2020 Oct; 87(5):395-404. PubMed ID: 32422338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
    Corbett EJM; Pentony P; McGill NW
    Int J Rheum Dis; 2017 Jul; 20(7):894-897. PubMed ID: 28205336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to the 2012 American College of Rheumatology (ACR) Guidelines for Management of Gout: A Survey of Brazilian Rheumatologists.
    Vargas-Santos AB; Castelar-Pinheiro Gda R; Coutinho ES; Schumacher HR; Singh JA; Schlesinger N
    PLoS One; 2015; 10(8):e0135805. PubMed ID: 26274585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in the management of gout is vital and overdue: an audit from a UK primary care medical practice.
    Cottrell E; Crabtree V; Edwards JJ; Roddy E
    BMC Fam Pract; 2013 Nov; 14():170. PubMed ID: 24225170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients.
    Janssen CA; Jansen TLTA; Oude Voshaar MAH; Vonkeman HE; van de Laar MAFJ
    Rheumatol Int; 2017 Sep; 37(9):1435-1440. PubMed ID: 28748426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort.
    Liang N; Sun M; Sun R; Xu T; Cui L; Wang C; Ma L; Cheng X; Xue X; Sun W; Yuan X; Zhang H; Li H; He Y; Ji A; Wu X; Li C
    Arthritis Res Ther; 2019 Sep; 21(1):200. PubMed ID: 31477161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
    Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GOSPEL 3: Management of gout by primary-care physicians and office-based rheumatologists in France in the early 21st century - comparison with 2006 EULAR Recommendations.
    Goossens J; Lancrenon S; Lanz S; Ea HK; Lambert C; Guggenbuhl P; Saraux A; Delva C; Sahbane S; Lioté F
    Joint Bone Spine; 2017 Jul; 84(4):447-453. PubMed ID: 28411137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift.
    Khanna P; Khanna D; Storgard C; Baumgartner S; Morlock R
    Postgrad Med; 2016 Jan; 128(1):34-40. PubMed ID: 26578028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A nurse-led, rheumatologist-assisted telemedicine intervention for dose escalation of urate-lowering therapy in gout.
    Phang KF; Santosa A; Low BPL; Tan PSH; Khong ZW; Lim AYN; Teng GG; Tay SH
    Int J Rheum Dis; 2020 Aug; 23(9):1136-1144. PubMed ID: 32483906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations.
    Roddy E; Zhang W; Doherty M
    Ann Rheum Dis; 2007 Oct; 66(10):1311-5. PubMed ID: 17504843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shared decision-making in gout treatment: a national study of rheumatology provider opinion and practice.
    Singh JA; Richards JS; Chang E; Toupin-April K; Barton JL
    Clin Rheumatol; 2021 Feb; 40(2):693-700. PubMed ID: 32997317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of gout by Moroccan rheumatologists: a Moroccan Society for Rheumatology National Survey.
    Moulay Berkchi J; Rkain H; Benbrahim L; Aktaou S; Lazrak N; Faiz S; Ahid S; Abouqal R; Labzizi S; Ouzeddoun N; Oukerraj L; Hmamouchi I; Hajjaj-Hassouni N; Allali F
    Rheumatol Int; 2020 Sep; 40(9):1399-1408. PubMed ID: 32447422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A joint effort over a period of time: factors affecting use of urate-lowering therapy for long-term treatment of gout.
    Richardson JC; Liddle J; Mallen CD; Roddy E; Hider S; Prinjha S; Ziebland S
    BMC Musculoskelet Disord; 2016 Jun; 17():249. PubMed ID: 27267878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares.
    Choi HJ; Lee CH; Lee JH; Yoon BY; Kim HA; Suh CH; Choi ST; Song JS; Joo HY; Choi SJ; Lee JS; Shin KC; Baek HJ
    Int J Rheum Dis; 2017 Apr; 20(4):497-503. PubMed ID: 25160939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective.
    Smolen LJ; Gahn JC; Mitri G; Shiozawa A
    Clin Ther; 2016 Jul; 38(7):1710-25. PubMed ID: 27269247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study.
    Kim A; Kim Y; Kim GT; Ahn E; So MW; Lee SG
    Clin Rheumatol; 2020 Dec; 39(12):3769-3776. PubMed ID: 32458236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring and Achievement of Target Serum Urate Among Gout Patients Receiving Long-Term Urate-Lowering Therapy in the American College of Rheumatology RISE Registry.
    Hammam N; Li J; Kay J; Izadi Z; Yazdany J; Schmajuk G
    Arthritis Care Res (Hoboken); 2023 Jul; 75(7):1544-1552. PubMed ID: 36039961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.